FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI, Brad ROSBROOK, Kathrine FERNANDEZ, Jiří TOMÁŠEK, Espen THIIS-EVENSEN, Matthew KULKE and Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncology. London: Future Medicine Ltd., 2019, vol. 15, No 17, p. 1997-2007. ISSN 1479-6694. Available from: https://dx.doi.org/10.2217/fon-2018-0934. |
Other formats:
BibTeX
LaTeX
RIS
@article{1615257, author = {Fazio, Nicola and Martini, JeanandFrancois and Croitoru, Adina E. and Schenker, Michael and Li, Sherry and Rosbrook, Brad and Fernandez, Kathrine and Tomášek, Jiří and ThiisandEvensen, Espen and Kulke, Matthew and Raymond, Eric}, article_location = {London}, article_number = {17}, doi = {http://dx.doi.org/10.2217/fon-2018-0934}, keywords = {biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF}, language = {eng}, issn = {1479-6694}, journal = {Future Oncology}, title = {Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors}, url = {http://dx.doi.org/10.2217/fon-2018-0934}, volume = {15}, year = {2019} }
TY - JOUR ID - 1615257 AU - Fazio, Nicola - Martini, Jean-Francois - Croitoru, Adina E. - Schenker, Michael - Li, Sherry - Rosbrook, Brad - Fernandez, Kathrine - Tomášek, Jiří - Thiis-Evensen, Espen - Kulke, Matthew - Raymond, Eric PY - 2019 TI - Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors JF - Future Oncology VL - 15 IS - 17 SP - 1997-2007 EP - 1997-2007 PB - Future Medicine Ltd. SN - 14796694 KW - biomarkers KW - efficacy KW - pancreatic neuroendocrine tumor KW - sunitinib KW - VEGF UR - http://dx.doi.org/10.2217/fon-2018-0934 L2 - http://dx.doi.org/10.2217/fon-2018-0934 N2 - Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes. ER -
FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI, Brad ROSBROOK, Kathrine FERNANDEZ, Jiří TOMÁŠEK, Espen THIIS-EVENSEN, Matthew KULKE and Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. \textit{Future Oncology}. London: Future Medicine Ltd., 2019, vol.~15, No~17, p.~1997-2007. ISSN~1479-6694. Available from: https://dx.doi.org/10.2217/fon-2018-0934.
|